NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.70 +0.02 (+2.95%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.67▼$0.7150-Day Range$0.53▼$0.9952-Week Range$0.52▼$1.54Volume1.21 million shsAverage Volume2.89 million shsMarket Capitalization$123.40 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vaxart alerts: Email Address Vaxart MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside329.9% Upside$3.00 Price TargetShort InterestHealthy7.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 2 Articles This WeekInsider TradingAcquiring Shares$13,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector432nd out of 936 stocksBiological Products, Except Diagnostic Industry64th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days.Read more about Vaxart's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.00% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently decreased by 11.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 2.9 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vaxart this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.55) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Vaxart Stock (NASDAQ:VXRT)Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More VXRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VXRT Stock News HeadlinesJuly 23 at 6:11 AM | americanbankingnews.comVaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average of $0.91July 18, 2024 | americanbankingnews.comVaxart (NASDAQ:VXRT) & Vir Biotechnology (NASDAQ:VIR) Critical SurveyJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 17, 2024 | americanbankingnews.comAnalyzing Vaxart (NASDAQ:VXRT) and MiNK Therapeutics (NASDAQ:INKT)June 17, 2024 | globenewswire.comVaxart Provides Business UpdateJune 13, 2024 | globenewswire.comVaxart Announces $40 Million Underwritten Offering of Common StockJune 13, 2024 | globenewswire.comVaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateMay 23, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | insidermonkey.comVaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comVaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...May 13, 2024 | globenewswire.comVaxart Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 12, 2024 | markets.businessinsider.comVaxart earnings preview: what to expectMay 7, 2024 | finance.yahoo.comVaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13April 30, 2024 | globenewswire.comVaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating MothersApril 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?March 27, 2024 | globenewswire.comVaxart to Present at World Vaccine Congress Washington 2024 on April 3March 20, 2024 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+340.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-920.00% Pretax Margin-916.88% Return on Equity-121.06% Return on Assets-79.98% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio3.14 Sales & Book Value Annual Sales$7.38 million Price / Sales16.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.79Miscellaneous Outstanding Shares176,840,000Free Float171,533,000Market Cap$120.36 million OptionableOptionable Beta0.65 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Steven Lo (Age 57)President, CEO & Director Mr. Phillip Eric Lee (Age 36)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Raymond D. Stapleton Jr. (Age 53)Ph.D., Chief Technology Officer Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementDr. Rajesh Kapoor Ph.D.Senior Vice President of QualityKey CompetitorsAthira PharmaNASDAQ:ATHAAligos TherapeuticsNASDAQ:ALGSInovio PharmaceuticalsNASDAQ:INOAura BiosciencesNASDAQ:AURAEditas MedicineNASDAQ:EDITView All CompetitorsInsiders & InstitutionsSequoia Financial Advisors LLCBought 97,000 shares on 7/16/2024Ownership: 0.055%W. Mark WatsonBought 20,000 shares on 6/18/2024Total: $13,600.00 ($0.68/share)RA Capital Management L.P.Bought 15,384,615 shares on 5/17/2024Ownership: 8.700%Tidal Investments LLCBought 43,449 shares on 5/17/2024Ownership: 0.025%Vanguard Group Inc.Bought 1,404,391 shares on 5/10/2024Ownership: 4.778%View All Insider TransactionsView All Institutional Transactions VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.5728 at the beginning of 2024. Since then, VXRT shares have increased by 21.8% and is now trading at $0.6978. View the best growth stocks for 2024 here. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) released its quarterly earnings results on Monday, May, 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The biotechnology company earned $2.18 million during the quarter. Vaxart had a negative trailing twelve-month return on equity of 121.06% and a negative net margin of 920.00%. When did Vaxart's stock split? Shares of Vaxart reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. Who are Vaxart's major shareholders? Vaxart's top institutional investors include Sequoia Financial Advisors LLC (0.05%). Insiders that own company stock include W Mark Watson, Fuad Ahmad, Robert A Yedid, Sean Tucker and Margaret Echerd. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and ADMA Biologics (ADMA). This page (NASDAQ:VXRT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
